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Is There Room for Second-Line Treatment
of Pleural MalignantMesothelioma?
Malignantpleuralmesothelioma(MPM) is character-
ized by a bad prognosis and modest activity of sys-
temic treatment. Currently, there is no clear agreement
on the clinical role of second-line chemotherapy in pa-
tients with MPM; nevertheless, early case study re-
ports including somepretreated patients had provided
evidence thatadditional responsesarepossiblewith the
use of further chemotherapy1 after the failure of first-
line treatment.
Unfortunately, the evidence supporting the effi-
cacy of second-line treatment in this setting is globally
weak. A randomized phase 3 trial, enrolling 243
patients, compared pemetrexed plus best supportive
care vs best supportive care alone in patients previ-
ously treated with a first-line regimen not including
pemetrexed. When this study was published, how-
ever, the use of pemetrexed in combination with cis-
platin had been already accepted as standard first-line
treatment. The study showed a statistically significant
increase in objective response rate, disease control
rate, and time to progression for pemetrexed, but
without significant benefit in overall survival.2
Whether the benefit in other end points, in the
absence of difference in survival, could be considered
sufficient to recommend second-line pemetrexed for
clinical practice is debatable. In any case, the trial
recruited patients who were pemetrexed naive, which
greatly reduces the current applicability of these
results, with pemetrexed being part of first-line treat-
ment in the majority of patients now. Can we consider
the external validity of these results useful for clinical
practice? Probably not.
Evenwhenwe consider the shift frompemetrexed
toother chemotherapydrugs, likevinorelbine, their use
as second-line treatment isbasedonsmall, nonrandom-
ized series. Following previous experience in the first-
line setting,3 weekly vinorelbine was tested within a
single-center phase 2 open-label study in 63 patients
with previous exposure to chemotherapy. Like all the
single-arm trials, the results obtained in this series of
patients are at strong risk of being conditioned by se-
lectionbias:median intervalbetweentheendof thefirst-
line chemotherapy and the start of theweekly second-
linevinorelbinewas6months,mostpatientshadagood
performance status, all were classified as low risk ac-
cording to theEuropeanOrganization for Research and
Treatment of Cancer prognostic score, andmedian age
of this highly selected population was 59 years. A total
of 10 partial responses (16%)were observed, and a fur-
ther43patients (68%)hadstablediseasedefinedasno
evidence of progression for 6 months. Median overall
survival was 9.6 months. However, can we trust in the
reproducibility of these results in unselected patients,
with a shorter treatment-free interval, older age, and
worse performance status? Probably not.
Similarly, rechallenge with platinum-pemetrexed
chemotherapy is sometimesconsidered inpatientswho
have obtained a long progression-free interval, but the
evidence supporting this strategy is again weak. This
strategy isprobablymoresupportedbytheanalogywith
the rechallenge in other solid tumors where platinum-
based therapy is used, rather than by data specifically
produced in patientswithMPM. In this specific setting,
the rechallengehasbeenexploredbyCeresoli et al,4de-
scribing theoutcomeofpatientswhohadobtainedpro-
longed progression-free survival (PFS) (greater than 3
months) with the previous first-line treatment. Thirty-
one patients were included in the study, but there was
heterogeneity in the treatmentadopted: 15patientshad
a rechallengewithsingle-agentpemetrexedalone,while
16 had a real rechallenge with both drugs. One patient
experienceda complete response,whereas apartial re-
sponsewas achieved in 5 patients, producing amodest
overallobjective responserateof 19%,andanoveralldis-
ease control rate of 48%. Is this evidence sufficient to
consider rechallenge with pemetrexed-based chemo-
therapy as a second-line treatment option in patients
with MPM? Probably not.
Considering this absence of robust evidence sup-
porting theuseof second-line treatment in clinical prac-
tice, what is the position of existing guidelines? Na-
tional Comprehensive Cancer Network (NCCN) Clinical
PracticeGuidelines seem to support the use of second-
line treatment. In fact, although specifying that limited
data are available to guide the choice, NCCNguidelines
state that “second-line chemotherapy options include
pemetrexed (if not administered as first-line therapy),
vinorelbine, or gemcitabine, and data suggest that re-
challengingwithpemetrexed is effective if patients had
agoodresponse to first-linepemetrexed.”5Moving from
the United States to Europe, current guidelines of the
European Society of Medical Oncology, published in
2015, state that, given the absenceof standard second-
line or further-line therapy, it is recommended that pa-
tients who are in good clinical condition at disease pro-
gressionafter first-line treatmentshouldbeenrolled into
clinical trials.6 There is no explicit recommendation for
patients outside the opportunity of clinical trials, al-
though the statement that “single agentvinorelbinehas
shown useful activity in phase II trials” implies that, al-
thoughnot standard, second-line treatmentcanbecon-
sidered in clinical practice. Italian experts participating
intheThird ItalianConsensusConferenceforMPMstated
that, inpatientsprogressingaftera first-linepemetrexed-
basedregimen, there isnostandardsecond-line therapy,
andpatientsshouldbeencouragedtoparticipate inclini-
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cal trials.7 However, the next recommendation in the same docu-
ment emphasizes that, outside clinical trials, single-agent chemo-
therapy couldbeapossibleoption forpalliation, although thepanel
was not unanimous about this recommendation.
What shallwedo in clinical practice?Of course, patients should
be adequately informed to contribute to the decision. Sharing the
information with them openly and explaining that even best sup-
portive care,without further active treatment,wouldbeanaccept-
able treatment option should be amust-do.
Patients should be encouraged toparticipate in trials, but clini-
cal trials should be better designed. There is a huge variety of on-
going trials at themoment.Theoncologic community shouldbe firm
and clear on what we want from an interventional trial conducted
in the second-line setting. First, trials shouldbe randomized.Weac-
knowledge that observational or retrospective studies are helpful
to producehypothesis-generating evidence, but in this setting, like
in the majority of clinical settings, they will never change practice.
Furthermore, given the heterogeneity in prognosis and the diffi-
culty of interpreting a single-armexperiencewithout a comparator
arm, we believe that a control arm is needed to correctly interpret
theoutcomeofpatients treatedwith theexperimental drug. For in-
stance, if we consider the randomized phase 2 trial testing the ad-
ditionofbevacizumabtocisplatinandgemcitabineas first-line treat-
ment of patientswithMPM, the experimental treatment produced
amedianprogression-freesurvivalof6.9monthsandamedianover-
all survivalof 15.6months.8Theseresults, ifproducedwithinasingle-
arm trial, would have been probably judged as promising. Unfortu-
nately, the outcome of patients assigned to the control arm of the
same trial was superimposable, without any significant difference
between the groups. Probably, the samewould happen in the sec-
ond-linesetting, considering that theheterogeneity inprognosisand
the risk of selectionbias canbeevenhigher than in patients eligible
for first-line treatment. Given the absence of treatments of proven
efficacy, placebo is acceptable for patients assigned to the control
arm, althoughwe understand that the presence of an armwithout
active treatment can reduce the acceptability of the trial.
Patients enrolled in the trials should be well balanced accord-
ing to existing prognostic scores. Particularly, patients should be
stratifiedbasedonthedurationofdiseasecontrolobtainedwith first-
line chemotherapy. This is a prognostic factor, but could be also an
intriguing predictive marker for second-line chemotherapy, repre-
senting what is routinely called “platinum sensitivity.”
PatientswithMPMwhohad responded toplatinum-basedche-
motherapyandhaveaPFSgreater than6monthsmighthaveamore
responsive cancer, while patients with very short PFS have rather
aggressive mesothelioma, unlikely responsive to further treat-
ment. For instance, there are trials exploring immunotherapy in this
setting, either in setupor recruitingat themoment, suchas theCon-
firmtrial (pembrolizumab,clinicaltrials.gov identifierNCT02083484)
and the BIB296 (tremelimumab and durvalumab, clinicaltrials.gov
identifier NCT02588131). As far as we know, neither of them has a
PFS stratification like the one we have proposed. It should be con-
sidered that an imbalance in accrual between the treatment arms
will have a potentially negative impact on the final trial results.
In conclusion,we think that, at themoment, the real benefit as-
sociatedwith the administration of further active treatment to pa-
tients with MPM whose first-line treatment has failed is uncertain
atbest.Ofcourse, this shouldnot implyanihilisticvision.Onthecon-
trary, clinical research is vital to obtain progress in this setting, and
well-designed clinical trials are strongly needed.
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